@article{article_364345, title={Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis}, journal={Ortadoğu Tıp Dergisi}, volume={10}, pages={498–505}, year={2018}, DOI={10.21601/ortadogutipdergisi.364345}, author={Ucan, Bekir and Kebapci, M. Nur and Uslu, Sema and Kara, Mehmet and Akcar Degirmenci, Nevbahar and Oner, Setenay}, keywords={Visfatin,otoimmüne hipotiroidi,ateroskleroz}, abstract={<p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us">Aim: </span> </b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us"> Visfatin/pre-B cell enhancement factor stimulates the
production of inflammatory cytokines released from adipose tissue such as TNF-α
and IL-6, which are shown to be related to the pathogenesis of insulin
resistance, diabetes, dyslipidemia, inflammation, autoimmune diseases, and
atherosclerosis. Our aim was to evaluate plasma visfatin concentrations in
patients with autoimmune hypothyroidism and its relationship with thyroid
autoimmunity and atherosclerosis. </span> <span style="font-family:’Times New Roman’, serif;"> </span> </p> <p> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us">Material and Method: </span> </b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us"> Thirty-five patients with newly diagnosed Hashimoto’s thyroiditis
(32 women/3 men, mean age 43.8±9.6 years) and 18 healthy controls (17 women/1
men, mean age 43.3±5.2 years) were enrolled in the study. Anthropometric
measurements, carotid intima-media thickness (CIMT), serum anti-Tg, anti-TPO,
hsCRP, homocysteine, lipo(a), ApoA, ApoB1, β-2 microglobulin, insulin, glucose,
visfatin, IL6, TNF-α, oxidized-LDL concentrations, lymphocyte subgroups and
lipid profile were investigated both before and after thyroid hormone
replacement therapy. Serum visfatin concentrations were determined by
enzyme-linked immunosorbent assay (ELISA). </span> <span style="font-family:’Times New Roman’, serif;"> </span> </p> <p> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us">Results: </span> </b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us"> Mean serum visfatin concentrations were similar between autoimmune
hypothyroidism group and control group (6.29 ± 1.63 ng/ml to 6.36 ± 1.51 ng/ml,
p>0.05) and it was not correlated with thyroid autoimmunity and
atherosclerosis markers.  Plasma
visfatin, oxidized LDL, IL-6, and TNF-α concentrations did not differ
statistically between the control group and hypothyroid patients both before
and after the therapy. The cardiovascular risk factors for systolic and
diastolic blood pressure, HOMA-IR index, triglyceride, Apo B and ApoB/ApoA,
homocysteine, β-2 microglobulin, and CIMT were found to be elevated in
patients. Ox-LDL, cholesterol, homocysteine, and proteinuria concentrations
were positively correlated with anti-Tg concentrations. </span> <span style="font-family:’Times New Roman’, serif;"> </span> </p> <p> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:200%;"> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us">Conclusion: </span> </b> <span lang="en-us" style="font-family:’Times New Roman’, serif;" xml:lang="en-us"> Serum visfatin concentrations were not associated with thyroid
autoimmunity and atherosclerosis.  </span> <span style="font-family:’Times New Roman’, serif;"> </span> </p> <p> </p> <p> </p> <p> </p>}, number={4}, publisher={MEDİTAGEM Ltd. Şti.}